The much anticipated results from two phase III studies evaluating the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibition in patients with advanced-stage breast cancer harbouring a germline mutation in BRCA1/2 have established new therapeutic opportunities and yet, have left us with several ongoing questions.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
CNS Drugs Open Access 06 December 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA tutation. N. Engl. J. Med. 377, 523–533 (2017).
Robson, M. E. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558–566 (2019).
Litton, J. K. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N. Engl. J. Med. 379, 753–763 (2018).
Litton, J. K. et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann. Oncol. 31, 1526–1535 (2020).
Ettl, J. et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann. Oncol. 29, 1939–1947 (2018).
Dieras, V. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 1269–1282 (2020).
Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. https://doi.org/10.1016/j.annonc.2020.09.010 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.P-S. is a member of the advisory board and speaker’s bureau of AstraZeneca and Pfizer. F.C. declares no competing interests.
Rights and permissions
About this article
Cite this article
Paluch-Shimon, S., Cardoso, F. PARP inhibitors coming of age. Nat Rev Clin Oncol 18, 69–70 (2021). https://doi.org/10.1038/s41571-020-00452-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-020-00452-2
This article is cited by
-
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
CNS Drugs (2023)
-
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Nature Reviews Drug Discovery (2022)
-
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Nature Reviews Clinical Oncology (2022)
